| |
| |
|
| Insider
Information: |
Gibson Christopher |
| Relationship: |
Chief Executive Office... |
| City: |
Salt Lake City |
| State: |
UT |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
1 |
|
| Direct
Shares |
834,820 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$7,212,845 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
834,820 |
|
|
| Total
Value |
$7,212,845 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
|
|
| Stock
price went down : |
|
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Recursion Pharmaceuticals, Inc. |
RXRX |
Chief Executive Office... |
2024-05-02 |
834,820 |
2024-04-04 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| RXRX |
Recursion Pharmaceuticals... |
Chief Executive Officer |
• • – |
2024-05-02 |
4 |
AS |
$8.47 |
$423,500 |
D/D |
(50,000) |
834,820 |
0 |
% |
|
| RXRX |
Recursion Pharmaceuticals... |
Chief Executive Officer |
• • – |
2024-05-02 |
4 |
A |
$0.00 |
$0 |
D/D |
21,296 |
856,116 |
0 |
- |
|
| RXRX |
Recursion Pharmaceuticals... |
Chief Executive Officer |
• • – |
2024-05-01 |
4 |
AS |
$7.73 |
$386,500 |
D/D |
(50,000) |
863,524 |
0 |
% |
|
| RXRX |
Recursion Pharmaceuticals... |
Chief Executive Officer |
• • – |
2024-05-01 |
4 |
GD |
$0.00 |
$0 |
D/D |
25,000 |
913,524 |
0 |
- |
|
| RXRX |
Recursion Pharmaceuticals... |
Chief Executive Officer |
• • – |
2024-04-04 |
4 |
AS |
$9.02 |
$360,800 |
D/D |
(40,000) |
938,524 |
0 |
% |
|
| RXRX |
Recursion Pharmaceuticals... |
Chief Executive Officer |
• • – |
2024-04-04 |
4 |
A |
$0.00 |
$0 |
I/I |
25,000 |
25,000 |
0 |
- |
|
| RXRX |
Recursion Pharmaceuticals... |
Chief Executive Officer |
• • – |
2024-04-04 |
4 |
AS |
$9.02 |
$225,500 |
I/I |
(25,000) |
0 |
0 |
% |
|
| RXRX |
Recursion Pharmaceuticals... |
Chief Executive Officer |
• • – |
2024-04-03 |
4 |
AS |
$8.84 |
$221,000 |
I/I |
(25,000) |
0 |
0 |
% |
|
| RXRX |
Recursion Pharmaceuticals... |
Chief Executive Officer |
• • – |
2024-04-03 |
4 |
A |
$0.00 |
$0 |
I/I |
25,000 |
25,000 |
0 |
- |
|
| RXRX |
Recursion Pharmaceuticals... |
Chief Executive Officer |
• • – |
2024-04-03 |
4 |
AS |
$8.84 |
$353,600 |
D/D |
(40,000) |
978,524 |
0 |
% |
|
| RXRX |
Recursion Pharmaceuticals... |
Chief Executive Officer |
• • – |
2024-04-03 |
4 |
GD |
$0.00 |
$0 |
D/D |
25,000 |
1,018,524 |
0 |
- |
|
| RXRX |
Recursion Pharmaceuticals... |
Chief Executive Officer |
• • – |
2024-03-28 |
4 |
GD |
$0.00 |
$0 |
D/D |
25,000 |
1,083,524 |
0 |
- |
|
| RXRX |
Recursion Pharmaceuticals... |
Chief Executive Officer |
• • – |
2024-03-28 |
4 |
AS |
$10.10 |
$404,000 |
D/D |
(40,000) |
1,043,524 |
0 |
% |
|
| RXRX |
Recursion Pharmaceuticals... |
Chief Executive Officer |
• • – |
2024-03-28 |
4 |
A |
$0.00 |
$0 |
I/I |
25,000 |
25,000 |
0 |
- |
|
| RXRX |
Recursion Pharmaceuticals... |
Chief Executive Officer |
• • – |
2024-03-28 |
4 |
AS |
$10.10 |
$252,500 |
I/I |
(25,000) |
0 |
0 |
% |
|
| RXRX |
Recursion Pharmaceuticals... |
Chief Executive Officer |
• • – |
2024-03-06 |
4 |
GD |
$0.00 |
$0 |
D/D |
10,000 |
1,104,919 |
0 |
- |
|
| RXRX |
Recursion Pharmaceuticals... |
Chief Executive Officer |
• • – |
2024-03-06 |
4 |
A |
$0.00 |
$0 |
D/D |
10,000 |
1,114,919 |
0 |
- |
|
| RXRX |
Recursion Pharmaceuticals... |
Chief Executive Officer |
• • – |
2024-03-06 |
4 |
AS |
$11.86 |
$430,682 |
D/D |
(36,319) |
1,108,524 |
0 |
% |
|
| RXRX |
Recursion Pharmaceuticals... |
Chief Executive Officer |
• • – |
2024-03-06 |
4 |
A |
$0.00 |
$0 |
I/I |
25,000 |
1,000 |
0 |
- |
|
| RXRX |
Recursion Pharmaceuticals... |
Chief Executive Officer |
• • – |
2024-03-06 |
4 |
AS |
$11.55 |
$288,823 |
I/I |
(25,000) |
0 |
0 |
% |
|
| RXRX |
Recursion Pharmaceuticals... |
Chief Executive Officer |
• • – |
2024-03-06 |
4 |
OE |
$2.48 |
$176,384 |
D/D |
39,924 |
1,144,843 |
0 |
- |
|
| RXRX |
Recursion Pharmaceuticals... |
Chief Executive Officer |
• • – |
2024-02-15 |
4 |
D |
$12.43 |
$138,570 |
D/D |
(11,148) |
1,104,919 |
0 |
- |
|
| RXRX |
Recursion Pharmaceuticals... |
Chief Executive Officer |
• • – |
2024-02-09 |
4 |
D |
$10.09 |
$32,621 |
D/D |
(3,233) |
1,116,067 |
0 |
- |
|
| RXRX |
Recursion Pharmaceuticals... |
Chief Executive Officer |
• • – |
2024-02-09 |
4 |
A |
$0.00 |
$0 |
D/D |
344,597 |
1,119,300 |
0 |
- |
|
| RXRX |
Recursion Pharmaceuticals... |
Chief Executive Officer |
• • – |
2024-02-07 |
4 |
A |
$0.00 |
$0 |
D/D |
10,000 |
801,725 |
0 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
